Akums Drugs and Pharmaceuticals will acquire Oriflame India's manufacturing facilities in Roorkee and Noida for ₹56 crore. The deal allows the company to enter the color cosmetics market and reduce its reliance on core pharmaceutical manufacturing. The transaction is expected to be completed by August 31, 2026.
Detailed Coverage
Akums Drugs and Pharmaceuticals announced on Thursday a deal to purchase the manufacturing operations of Oriflame India Ltd for ₹56 crore. This acquisition will be handled by Pure and Cure Healthcare Pvt Ltd, a wholly-owned subsidiary of Akums. The deal includes two manufacturing plants—one in Roorkee, Uttarakhand, and another in Noida, Uttar Pradesh—along with a leased warehouse in Noida.
Strategic Shift Toward Personal Care
For Akums, which is primarily known as a contract manufacturer for pharmaceutical companies, this move signals a broader attempt to move into adjacent consumer categories. By acquiring these ready-to-use facilities, the company gains immediate capacity to produce skincare, hair care, and color cosmetics products. The management indicated that this is part of a plan to lower the company's concentration on drug manufacturing by entering the high-growth beauty and wellness segment.
Investor Context and Financial Impact
This cash-funded acquisition is relatively small compared to the company’s overall scale, meaning it is unlikely to put major pressure on its balance sheet. However, the success of this move will depend on how effectively the company can integrate these new facilities and attract beauty brands as new clients. The cosmetics industry often operates with different regulatory requirements and demand cycles compared to the pharmaceutical sector.
Akums currently operates as a large-scale manufacturer for other pharmaceutical brands, and investors often track the company's ability to maintain profit margins while managing large manufacturing operations. Moving into cosmetics introduces new competitive dynamics, as the company will now have to compete in a market driven by changing consumer trends and marketing intensity, rather than just manufacturing efficiency.
Monitoring Future Integration
As the deal is set to close by August 31, 2026, the key monitorable for investors will be how the company scales production in these new facilities. Shareholders may also look for updates in future earnings reports regarding the contribution of the cosmetics business to overall revenue and whether this diversification improves the company’s return on capital in the long run. The company will also need to demonstrate that it can maintain its core pharmaceutical margins while navigating the different cost structures of the consumer beauty business.